Asset profile

tilrekimig · Pfizer (PFE)

Indication: moderate-to-severe atopic dermatitis
Also known as: PF-07275315

Company

Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers …

Start live analysis of PFE Run 8-agent AI analysis

On the calendar

Oct 2026

Oct 19, 2026

3 days ago

PFEPfizer

tilrekimig: Phase 2 trial NCT05995964 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionOutcome not recordedClinicalTrials.gov

Mar 2027

Mar 8, 2027

in 137 days

PFEPfizer

tilrekimig: Phase 2 trial NCT06977581 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Mar 2028

Mar 10, 2028

in 505 days

PFEPfizer

tilrekimig: Phase 3 trial NCT07765888 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Jun 2029

Jun 1, 2029

in 953 days

PFEPfizer

tilrekimig: Phase 3 trial NCT07772921 expected to finish collecting primary-endpoint data (topline results usually follow)

Rescheduled — was Jun 12, 2029

Trial primary completionClinicalTrials.gov

Oct 2030

Oct 24, 2030

in 1463 days

PFEPfizer

tilrekimig: Phase 2/Phase 3 trial NCT07363694 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

May 2034

May 12, 2034

in 2759 days

PFEPfizer

tilrekimig: Phase 3 trial NCT07839884 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Timeline

Newest first.

Oct 22, 2026

03:24 PM

PFEPfizer

tilrekimig · NCT07363694 registry update

Trial registry changeClinicalTrials.gov

Oct 15, 2026

03:25 PM

PFEPfizer

tilrekimig · NCT07765888 registry update

Trial registry changeClinicalTrials.gov

Oct 6, 2026

03:24 PM

PFEPfizer

tilrekimig · NCT07772921 registry update

Trial registry changeClinicalTrials.gov Open record

Oct 1, 2026

06:30 AM

PFEPfizer

Pfizer tilrekimig Phase 2 meets EASI-75 primary endpoint in atopic dermatitis

Topline resultsCompany press release Open record2 updates

Readiness checklist

Public facts only. We never publish an approval probability.

Updated Oct 22, 2026

Primary endpoint metFavourable

Pfizer tilrekimig Phase 2 meets EASI-75 primary endpoint in atopic dermatitis

Overall survival significant or trendingUnknown

US / Western patient shareFavourable

175 of 453 sites in the United States

Advisory committee scheduledFavourable

No advisory committee announced

PDUFA date extendedUnknown

Manufacturing inspection recordUnknown

No public inspection record

Company language signals (label discussions)Unknown

Same-class precedentUnknown

Related companies

Each relationship is backed by the filing that stated it.

PFEPfizerOwner

Company press release Oct 1, 2026

Verify every date against the linked primary source. Informational only. Not investment advice. SimianX is not affiliated with the FDA or the SEC.

Registered trials

Registry ID	Phase	Status	Primary completion	Enrollment	Sites
NCT05995964	Phase 2	Recruiting	Oct 19, 2026	340	52 of 98 sites in the United States
NCT07765888	Phase 3	Recruiting	Mar 10, 2028	375	14 of 21 sites in the United States
NCT06977581	Phase 2	Recruiting	Mar 8, 2027	252	36 of 137 sites in the United States
NCT07363694	Phase 2/3	Recruiting	Oct 24, 2030	1156	66 of 189 sites in the United States
NCT07839884	Phase 3	Not yet recruiting	May 12, 2034	1360
NCT07772921	Phase 3	Recruiting	Jun 1, 2029	1100	7 of 8 sites in the United States

More from Pfizer

Other drugs and candidates from the same company tracked in this sector.

atirmociclibHR+/HER2- advanced or metastatic breast cancer avutometinib + defactinibrecurrent low-grade serous ovarian cancer (LGSOC)cemsidomiderelapsed/refractory multiple myeloma COMIRNATY XFGCOVID-19 prevention in adults 65+ and individuals 5-64 with high-risk conditions enfortumab vedotin-ejfvmuscle-invasive bladder cancer (MIBC) as neoadjuvant and adjuvant treatment marstacimab-hncqhemophilia A or B with inhibitors (ages 12+, ≥35 kg)palbociclibHR+, HER2+ locally advanced or metastatic breast cancer maintenance treatment following induction pembrolizumabunresectable or metastatic TMB-H solid tumors PF-07307405Lyme disease PF-07872412pneumococcal disease PF-08046031all human diseases and disorders ritlecitinibnonsegmental vitiligo sigvotatug vedotinpreviously treated metastatic non-squamous non-small cell lung cancer talazoparibHRR gene-mutated metastatic castration-sensitive prostate cancer (mCSPC)tisotumab vedotinrecurrent or metastatic cervical cancer with disease progression on or after chemotherapy tucatinibmaintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction vepdegestrantER+/HER2-, ESR1-mutated advanced or metastatic breast cancer